mRNA-1189

BIOLOGICAL3 trials

Sponsors

ModernaTX, Inc.

Conditions

Epstein-Barr VirusEpstein-Barr Virus Infection

Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Active, not recruitingNCT05164094

ModernaTX, Inc.Epstein-Barr Virus Infection

Start: 2021-12-28End: 2027-08-18Updated: 2026-05-06

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Active, not recruitingNCT05831111

ModernaTX, Inc.Epstein-Barr Virus Infection

Start: 2023-04-05End: 2026-10-13Updated: 2026-08-11

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

RecruitingNCT07478952

ModernaTX, Inc.Epstein-Barr Virus

Start: 2026-03-17End: 2027-05-15Target: 120Updated: 2026-03-24